alnylam
This senior leadership role entails building and guiding a genetics research team focused on large-scale genetic studies, utilizing diverse data sources to discover genetic variants related to health and disease. The position involves designing analytical strategies, fostering innovation, and collaborating externally to advance translational genetics and drug discovery.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
alnylam didn’t post a salary, so this is our estimate from similar listings.
Scientist, Statistical Genetics
Alnylam Pharmaceuticals
Senior Scientist - Statistical Genetics
City Therapeutics
Senior / Principal Scientist, Statistical Genetics
State of Indiana
Principal Scientist, Translational Genetics
Cytokinetics
Statistical Genetics Platform Engineer
Eli Lilly and Company
Associate Manager, Statistical Genetics
Regeneron Pharmaceuticals